SG146692A1 - Melanin concentrating hormone antagonists - Google Patents

Melanin concentrating hormone antagonists

Info

Publication number
SG146692A1
SG146692A1 SG200807343-9A SG2008073439A SG146692A1 SG 146692 A1 SG146692 A1 SG 146692A1 SG 2008073439 A SG2008073439 A SG 2008073439A SG 146692 A1 SG146692 A1 SG 146692A1
Authority
SG
Singapore
Prior art keywords
independently
concentrating hormone
melanin concentrating
formula
compounds
Prior art date
Application number
SG200807343-9A
Other languages
English (en)
Inventor
Xiufeng Eric Hu
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SG146692A1 publication Critical patent/SG146692A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG200807343-9A 2003-10-01 2004-09-24 Melanin concentrating hormone antagonists SG146692A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50777303P 2003-10-01 2003-10-01
US53664004P 2004-01-15 2004-01-15

Publications (1)

Publication Number Publication Date
SG146692A1 true SG146692A1 (en) 2008-10-30

Family

ID=34426018

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807343-9A SG146692A1 (en) 2003-10-01 2004-09-24 Melanin concentrating hormone antagonists

Country Status (20)

Country Link
US (1) US7304065B2 (fr)
EP (1) EP1667958A2 (fr)
JP (1) JP2007508303A (fr)
KR (1) KR20060060047A (fr)
CN (1) CN101068773A (fr)
AR (1) AR045958A1 (fr)
AU (1) AU2004278352B2 (fr)
BR (1) BRPI0415051A (fr)
CA (1) CA2540826A1 (fr)
CO (1) CO5690589A2 (fr)
IL (1) IL174370A0 (fr)
IS (1) IS8360A (fr)
MA (1) MA28079A1 (fr)
MX (1) MXPA06003654A (fr)
NO (1) NO20061953L (fr)
PE (1) PE20050475A1 (fr)
RU (1) RU2006110272A (fr)
SG (1) SG146692A1 (fr)
TW (1) TW200526554A (fr)
WO (1) WO2005033063A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001160A1 (fr) * 2006-06-23 2008-01-03 The Procter & Gamble Company Antagonistes de l'hormone concentrant la mélanine
DK2041093T3 (da) * 2006-06-28 2010-08-02 Glaxo Group Ltd Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
JPWO2008044632A1 (ja) * 2006-10-06 2010-02-12 大正製薬株式会社 １−ナフチルアルキルピペリジン誘導体
EP2213655A1 (fr) * 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Procédés de purification de composés d'aminoalkyle de tétracycline
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2307377A1 (fr) * 2008-06-18 2011-04-13 Pfizer Limited Dérivés de nicotinamide
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
AR075402A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
EP2522657B1 (fr) * 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Dérivé d'indole

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206428A (en) 1989-11-16 1993-04-27 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthalene derivatives and preparation thereof
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH08506817A (ja) * 1993-02-12 1996-07-23 メルク エンド カンパニー インコーポレーテッド スピロ（２ｈ−１−ベンゾピラン−２，４′−ピペリジン）クラス▲ｉｉｉ▼抗不整脈薬
WO1994027597A1 (fr) 1993-05-21 1994-12-08 Smithkline Beecham Corporation Acides imidazolyl-alcenoiques antagonistes du recepteur de l'angiotensine ii
US5756496A (en) 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
DE4438029A1 (de) 1994-10-25 1996-05-02 Thomae Gmbh Dr K N.N-disubstituierte Benzocycloalkylamine, ihre Salze mit verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
WO1996030333A1 (fr) * 1995-03-27 1996-10-03 Smithkline Beecham Plc Derives amines bicycliques et leur utilisation comme agents neuroleptiques
DE19614718A1 (de) * 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
ATE390404T1 (de) 1997-02-27 2008-04-15 Takeda Pharmaceutical Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
CA2340100A1 (fr) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives sulfonyle
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001082925A1 (fr) * 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
DE60112791T2 (de) * 2000-12-22 2006-06-08 Schering Corp. Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
CN1582281A (zh) 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂
HUP0401656A3 (en) 2001-10-25 2012-05-02 Schering Corp Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them
CN1592739A (zh) 2001-11-26 2005-03-09 先灵公司 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
HUP0500034A2 (hu) 2001-12-04 2005-04-28 Schering Corporation N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2006503915A (ja) 2002-10-21 2006-02-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換テトラリンおよびインダンを用いたｘ症候群の治療
EP1631542A1 (fr) 2003-04-10 2006-03-08 Amgen, Inc. Composes bicycliques presentant une affinite pour les recepteurs de la bradykinine et compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
IS8360A (is) 2006-03-17
PE20050475A1 (es) 2005-10-05
WO2005033063A2 (fr) 2005-04-14
AU2004278352A1 (en) 2005-04-14
NO20061953L (no) 2006-06-13
CN101068773A (zh) 2007-11-07
MA28079A1 (fr) 2006-08-01
CO5690589A2 (es) 2006-10-31
MXPA06003654A (es) 2006-06-05
KR20060060047A (ko) 2006-06-02
AU2004278352B2 (en) 2008-10-30
EP1667958A2 (fr) 2006-06-14
CA2540826A1 (fr) 2005-04-14
RU2006110272A (ru) 2007-11-10
JP2007508303A (ja) 2007-04-05
WO2005033063A3 (fr) 2007-03-22
US20050075324A1 (en) 2005-04-07
US7304065B2 (en) 2007-12-04
TW200526554A (en) 2005-08-16
AR045958A1 (es) 2005-11-16
IL174370A0 (en) 2006-08-01
BRPI0415051A (pt) 2006-11-28

Similar Documents

Publication Publication Date Title
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
MY129408A (en) Disubstituted bicyclic, heterocycles, the preparation and the use thereof as pharmaceutical compositions
NZ520071A (en) 4-aminopiperidine derivatives and their use as medicine
TW221811B (fr)
TW367327B (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
HK1111999A1 (en) Spiroketal derivative and use thereof as diabetic medicine
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
RS115004A (en) Novel thiophenylglycoside derivatives,methods for production thereof, medicaments comprising said compounds and use thereof
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
EP1775289A4 (fr) Nouveaux dérivés imidazolidine
CA2337825A1 (fr) Heterocycles bicycliques disubstitues, leurs preparations et utilisationse comme compositions pharmaceutiques
YU56302A (sh) Derivati 8,8a-dihidro-indeno/1,2-d/taizola, koji su supstituisani u 8a-položaju,postupak za njihovu proizvodnju i njihova primena kod leka npr.kao anorektičnog sredstva
RS99804A (en) Novel compounds and their use
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
CA2256897A1 (fr) Derives de morphinane et usage medical de ces derniers
SG146692A1 (en) Melanin concentrating hormone antagonists
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
TR200001740T2 (tr) Mikrobisidal ve bitkiye bağışıklık kazandırıcı aktiviteleri olan tiyazol-türevleri
BR0208205A (pt) Derivados de benzimidazol moduladores de receptores de quimocinas
MX9706394A (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.